{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-0ZHV2YID/d5783fb3-8141-406f-a2fd-582c259ce32a/PDF","dcterms:extent":"183 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-0ZHV2YID/9ea7b024-fb17-4edf-857b-154d49a897d2/TEXT","dcterms:extent":"75 KB"}],"edm:TimeSpan":{"@rdf:about":"1994-2025","edm:begin":{"@xml:lang":"en","#text":"1994"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-0ZHV2YID","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-46R7GGHL"},{"@xml:lang":"sl","#text":"Medicinski razgledi"}],"dcterms:issued":"2001","dc:creator":["Ravnik, Janez","Ravnik, Maja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:40"},{"@xml:lang":"sl","#text":"str. 263-282"}],"dc:identifier":["ISSN:0025-8121","COBISSID:14497241","URN:URN:NBN:SI:doc-0ZHV2YID"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Medicinski razgledi"},"dc:subject":[{"@xml:lang":"en","#text":"Carcinoid heart disease"},{"@xml:lang":"en","#text":"Diagnosis"},{"@xml:lang":"en","#text":"Diagnostic use"},{"@xml:lang":"en","#text":"diagnostika"},{"@xml:lang":"en","#text":"Echocardiography"},{"@xml:lang":"sl","#text":"Ehokardiografija"},{"@xml:lang":"sl","#text":"Karcinoidna srčna bolezen"},{"@xml:lang":"sl","#text":"Karcinoidni tumor"},{"@xml:lang":"en","#text":"Malignant carcinoid syndrome"},{"@xml:lang":"en","#text":"Octreotide"},{"@xml:lang":"sl","#text":"Okteotid"},{"@xml:lang":"en","#text":"Physiopathology"},{"@xml:lang":"en","#text":"Statistics, nonparametric"},{"@xml:lang":"sl","#text":"Statistika neparametrična"},{"@xml:lang":"en","#text":"Therapy"},{"@xml:lang":"en","#text":"Tumor markers, biological"},{"@xml:lang":"sl","#text":"Tumorski markerji, biološki"},{"@xml:lang":"sl","#text":"tumorski označevalci"},{"@rdf:resource":"http://www.wikidata.org/entity/Q584992"}],"dcterms:temporal":{"@rdf:resource":"1994-2025"},"dc:title":{"@xml:lang":"sl","#text":"Povezanost biokemičnih označevalcev in ehokardiografskih značilnosti pri karcinoidni srčni bolezni| The relationship between tumor markers and echocardiographic findings in carcionid heart disease|"},"dc:description":[{"@xml:lang":"sl","#text":"Carcinoids are neuroendocrine tumors. They produce physiologically active substances which can cause carcinoid syndrome and carcinoid heart disease at higher concentrations. The characteristic changes seen in carcinoid heart disease are carcinoid endocardial plaques. The pathogenesis of carcinoid heartdisease is not completely understood. An attempt was made to show the differences in biochemical markers between two groups of patients: those with carcinoid heart disease and those without it. Through these differences we hoped to get some insight into the pathogenesis of carcinoid heart disease andto be able to verify the diagnostic value of these biochemical markers. Oneof the objectives was also to calculate the incidence of carcinoid heart disease in patients with carcinoid syndrome in Slovenia. Our hypotheses were as follows: 1. Levels of chromogranin A, 5-HIAA and TGF-beta1 will be significantly higher in the group with carcinoid heart disease compared to thecontrol group. 2. Concentrations of 5-HIAA before treatment with octreotidewill be significantly higher in the group with carcinoid heart disease compared to the control group. 3. Treatment with octreotide will not prevent the appearance of carcinoid heart disease. The study was prospective and included all patients in Slovenia who were diagnosed with and treated for carcinoid syndrome at the time. They were divided into two groups based on echocardiographic findings typical for carcinoid heart disease. Serum concentrations of chromogranin A were measured using RIA, urinary concentrations of 5-HIAA were measured using HPLC, and serum concentrations ofTGF-beta1 were measured using ELISA. Nonparametric tests were used for statistical analysis. (Abstract truncated at 2000 characters)"},{"@xml:lang":"sl","#text":"Karcinoidni tumorji so nevroendokrini tumorji. Izločajo različne fiziološko aktivne snovi, ki v povišanih koncentracijah lahko povzročajo karcinoidni sindrom in karcinoidno srčno bolezen. Značilne spremembe pri karcinoidni srčnibolezni so karcinoidne lehe na endokardu srca. Nastanek karcinoidne srčnebolezni ni dokončno pojasnjen. Sku*ali smo prikazati razlike v biokemičnih označevalcih med dvema skupinama bolnikov s karcinoidnim sindromom: tistih s karcinoidno srčno boleznijo in tistih brez nje. Preko razlik vbiokemičnih označevalcih smo želeli dobiti nekaj vpogleda v patogenezokarcinoidne srčne bolezni in preveriti njihovo diagnostično vrednost. Želeli smo ugotoviti pogostnost karcinoidne srčne bolezni pri bolnikih s karcinoidnim sindromom v Sloveniji. Naše hipoteze:1. Ravni kromogranina A, 5-hidroksiindolocetne kisline (5-HIAA) in transformirajočega rastnega dejavnika -beta1 (TGF-beta1) so pomembno višje v skupini s karcinoidno srčno boleznijo kot v skupini brez nje. 2. Koncentracije 5-HIAA sov skupini s karcinoidno srčno boleznijo pred začetkom zdravljenja z oktreotidom pomembno višje kot v skupini brez nje. 3. Zdravljenje z oktreotidom ne prepreči nastanka karcinoidne srčne bolezni. Prospektivna raziskava je zajela vse bolnike v Sloveniji, ki so bili v času raziskave vodeni pod diagnozo karcinoidnega sindroma. Glede na prisotnost ehokardiografskih sprememb smo bolnike razdelili v dve skupini: tiste s karcinoidno srčno boleznijo in tiste brez nje. Koncentracije kromogranina A v serumu smo določali z radioimunskih testom, koncentracije 5-HIAA v urinu z uporabo tekočinske kromatografije pod visokim pritiskom, koncentracije TGF-beta1 v serumu pa z encimskoimunskim testom. Dobljene rezultate smo statistično obdelali z uporabo neparametričnih testov. (Izvleček prekinjen pri2000 znakih)"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-0ZHV2YID","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-0ZHV2YID"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-0ZHV2YID/d5783fb3-8141-406f-a2fd-582c259ce32a/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo Medicinski razgledi"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-0ZHV2YID/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-0ZHV2YID"}}}}